Nature Gene Therapy Publishes Preclinical Data of Ocugen's OCU400 (NR2E3-AAV) Genetic Modifier to treat Retinitis Pigmentosa (RP)

Tuesday, March 3, 2020 1 min read

Key Takeaway: Nature Gene Therapy Publishes Preclinical Data of Ocugen's OCU400 (NR2E3-AAV) Genetic Modifier to treat Retinitis Pigmentosa (RP)

Full Press Release Details

Nature Gene Therapy Publishes Preclinical Data of Ocugen's OCU400 (NR2E3-AAV) Genetic Modifier to treat Retinitis Pigmentosa (RP).